#United States #financial results #BioLife Solutions #Bothell #Cell Therapy

BioLife Solutions Reports Impressive Q1 2026 Financial Results

BioLife Solutions, Inc. (Nasdaq: BLFS) has released its financial results for the first quarter of 2026, highlighting a remarkable 25% increase in total revenue over the same period last year. This surge, reaching $27.5 million, underscores the company's robust market presence as a developer and supplier of cell processing tools and services tailored for the cell and gene therapy (CGT) sector.

Strong Financial Performance

The results reflect a significant upward trajectory for BioLife, as the company reported a GAAP gross margin of 64%, despite a slight decrease from the previous year’s 67%. The net income for this quarter was recorded at $1.2 million, a considerable rise compared to $0.3 million in Q1 2025. Additionally, the non-GAAP adjusted EBITDA reached $6.2 million, which represents about 22% of total revenue.

Roderick de Greef, Chairman and CEO, expressed optimism about the outlook for the year, pointing to strong demand for BioLife's biopreservation media and healthy growth experienced across the broader product spectrum. He noted that the products are integrated into numerous commercial therapies, reinforcing the company's leadership in the industry.

Business Highlights

The first quarter of 2026 also saw BioLife Solutions achieving significant operational milestones. The company’s biopreservation media is currently employed in about 250 ongoing commercially sponsored clinical trials in the U.S., capturing over 70% of the market share. This includes more than 30 Phase III trials, indicating a robust presence in late-stage research.

Moreover, BioLife’s products, such as CellSeal vials and human Platelet Lysate (hPL), are utilized in over 35 clinical trials. The biopreservation media is embedded within 17 unique commercial CGT projects by the end of March 2026, with expectations of new approvals and geographic expansions in the upcoming months.

Financial Guidance for 2026

Looking ahead, BioLife Solutions has reiterated its financial guidance for the full year of 2026, projecting revenue between $112.5 million and $115.0 million. This projected revenue marks a growth of 17% to 20% compared to the revenue generated in 2025. The company also anticipates maintaining gross margins in the mid-60% range and expanding the adjusted EBITDA margin.

The management team is committed to delivering continued growth as the industry progresses, and they remain optimistic about the strategic opportunities that lie ahead in the CGT landscape.

The conference call discussing the company's quarter results is scheduled for today at 4:30 p.m. Eastern Time, allowing investors and stakeholders to gain further insights into BioLife’s performance and future strategies.

About BioLife Solutions

Founded to provide innovative solutions for biomedical applications, BioLife Solutions specializes in offering products and services essential to maintaining the viability and functionality of biologic materials. Their expertise plays a crucial role in the commercialization of new therapies, contributing towards the rapidly evolving field of cell and gene therapies. In light of recent financial success, BioLife is well-positioned to capitalize on ongoing advancements within the industry as it continues to foster strong partnerships and innovative product development.

For more information, you can visit their official website at www.biolifesolutions.com and follow the company on social media platforms.